Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002855724> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2002855724 endingPage "3057" @default.
- W2002855724 startingPage "3057" @default.
- W2002855724 abstract "Abstract Abstract #3057 Introduction: Patients (pts) with ER/PR/HER2 negative advanced breast cancer (triple negative, TN, basal-like) have limited treatment options and a poor prognosis. Ixabepilone (ixa), the first in a new class of antineoplastic agents, showed clinical benefit in combination with capecitabine (C) in 2 large clinical trials in metastatic breast cancer (MBC) pts either resistant to (study 046; JCO, 2007) or pretreated with anthracycline (A) and taxanes (T) (study 048). In 048, ixa + C, compared to C alone, demonstrated significant increases in PFS (HR 0.79 [0.69-0.90]) and ORR (43 vs. 29%). A trend towards increased OS was seen in both 048 (HR 0.90 [0.78-1.03]) and 046 (HR 0.90 [0.77-1.05]), which did not reach statistical significance. Here we present a pooled analysis of efficacy endpoints (ORR, PFS and OS) in pts with TN disease from these 2 phase III studies.
 Methods: 1973 pts with MBC previously treated with A and T were randomized in 2 phase III trials (046 and 048) to receive either ixa (40 mg/m2 IV over 3h Q3w) + C (1000 mg/m2 PO BID x14d Q3w) or C alone (1250 mg/m2 PO BID x14d Q3w). Due to the similarity of the study populations, individual pt data from both studies was pooled to better evaluate treatment effect within pre-planned patient subgroups.
 Results: 443 pts had TN disease in the two studies combined. ORR and PFS were superior in pts receiving combination therapy compared to those on C alone with a trend towards improved survival that did not reach statistical significance.
 
 Conclusions: Ixa + C is the first combination to show statistically significant PFS benefit in pts with advanced TN breast cancer from a pooled analysis of 2 phase III trials. Clinical benefit was consistently seen pts with TN disease in the individual studies as well. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 3057." @default.
- W2002855724 created "2016-06-24" @default.
- W2002855724 creator A5003980305 @default.
- W2002855724 creator A5019483256 @default.
- W2002855724 creator A5045165997 @default.
- W2002855724 creator A5049358292 @default.
- W2002855724 creator A5052906453 @default.
- W2002855724 creator A5065306642 @default.
- W2002855724 creator A5067033101 @default.
- W2002855724 creator A5067684052 @default.
- W2002855724 creator A5087297156 @default.
- W2002855724 date "2009-01-01" @default.
- W2002855724 modified "2023-09-26" @default.
- W2002855724 title "Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies." @default.
- W2002855724 doi "https://doi.org/10.1158/0008-5472.sabcs-3057" @default.
- W2002855724 hasPublicationYear "2009" @default.
- W2002855724 type Work @default.
- W2002855724 sameAs 2002855724 @default.
- W2002855724 citedByCount "29" @default.
- W2002855724 countsByYear W20028557242012 @default.
- W2002855724 countsByYear W20028557242014 @default.
- W2002855724 countsByYear W20028557242015 @default.
- W2002855724 countsByYear W20028557242016 @default.
- W2002855724 countsByYear W20028557242017 @default.
- W2002855724 countsByYear W20028557242021 @default.
- W2002855724 crossrefType "journal-article" @default.
- W2002855724 hasAuthorship W2002855724A5003980305 @default.
- W2002855724 hasAuthorship W2002855724A5019483256 @default.
- W2002855724 hasAuthorship W2002855724A5045165997 @default.
- W2002855724 hasAuthorship W2002855724A5049358292 @default.
- W2002855724 hasAuthorship W2002855724A5052906453 @default.
- W2002855724 hasAuthorship W2002855724A5065306642 @default.
- W2002855724 hasAuthorship W2002855724A5067033101 @default.
- W2002855724 hasAuthorship W2002855724A5067684052 @default.
- W2002855724 hasAuthorship W2002855724A5087297156 @default.
- W2002855724 hasConcept C121608353 @default.
- W2002855724 hasConcept C126322002 @default.
- W2002855724 hasConcept C143998085 @default.
- W2002855724 hasConcept C2776802502 @default.
- W2002855724 hasConcept C2777511904 @default.
- W2002855724 hasConcept C2777909004 @default.
- W2002855724 hasConcept C2779194965 @default.
- W2002855724 hasConcept C31760486 @default.
- W2002855724 hasConcept C526805850 @default.
- W2002855724 hasConcept C530470458 @default.
- W2002855724 hasConcept C535046627 @default.
- W2002855724 hasConcept C65409693 @default.
- W2002855724 hasConcept C71924100 @default.
- W2002855724 hasConcept C90924648 @default.
- W2002855724 hasConceptScore W2002855724C121608353 @default.
- W2002855724 hasConceptScore W2002855724C126322002 @default.
- W2002855724 hasConceptScore W2002855724C143998085 @default.
- W2002855724 hasConceptScore W2002855724C2776802502 @default.
- W2002855724 hasConceptScore W2002855724C2777511904 @default.
- W2002855724 hasConceptScore W2002855724C2777909004 @default.
- W2002855724 hasConceptScore W2002855724C2779194965 @default.
- W2002855724 hasConceptScore W2002855724C31760486 @default.
- W2002855724 hasConceptScore W2002855724C526805850 @default.
- W2002855724 hasConceptScore W2002855724C530470458 @default.
- W2002855724 hasConceptScore W2002855724C535046627 @default.
- W2002855724 hasConceptScore W2002855724C65409693 @default.
- W2002855724 hasConceptScore W2002855724C71924100 @default.
- W2002855724 hasConceptScore W2002855724C90924648 @default.
- W2002855724 hasIssue "2_Supplement" @default.
- W2002855724 hasLocation W20028557241 @default.
- W2002855724 hasOpenAccess W2002855724 @default.
- W2002855724 hasPrimaryLocation W20028557241 @default.
- W2002855724 hasRelatedWork W1989570758 @default.
- W2002855724 hasRelatedWork W1995136965 @default.
- W2002855724 hasRelatedWork W2062210103 @default.
- W2002855724 hasRelatedWork W2125689364 @default.
- W2002855724 hasRelatedWork W2156108617 @default.
- W2002855724 hasRelatedWork W2164817156 @default.
- W2002855724 hasRelatedWork W2225369932 @default.
- W2002855724 hasRelatedWork W2647762753 @default.
- W2002855724 hasRelatedWork W2806013813 @default.
- W2002855724 hasRelatedWork W3033574736 @default.
- W2002855724 hasVolume "69" @default.
- W2002855724 isParatext "false" @default.
- W2002855724 isRetracted "false" @default.
- W2002855724 magId "2002855724" @default.
- W2002855724 workType "article" @default.